SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCSRT.L Regulatory News (CSRT)

  • There is currently no data for CSRT

Rule 2.9 Announcement

12 Jul 2018 17:45

RNS Number : 5156U
Consort Medical PLC
12 July 2018
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

 

 

For immediate release

12 July 2018

 

Consort Medical plc

 

("Consort" or the "Company")

 

Rule 2.9 Announcement

 

In accordance with Rule 2.9 of the Code, Consort confirms that it has today issued 367 shares and therefore, as at the date of this announcement, it has issued share capital consisting of 49,288,618 ordinary shares of 10 pence each.

 

The increase in issued share capital is the result of Consort share options being exercised by certain former employees. The shares issued upon exercise of the options were admitted for trading on the Main Market of the London Stock Exchange as part of the block admission update announced on 27 June 2013.

 

There are no ordinary shares held in treasury. The ordinary shares trade on the Main Market of the London Stock Exchange. The International Securities Identification Number (ISIN) of the ordinary shares is GB0000946276.

 

The Company has an American Depositary Receipt ("ADR") programme for which The Bank of New York Mellon acts as depositary. One ADR represents one ordinary share in the Company, with ISIN US21030P1049. The ADRs trade in the over-the-counter market in the United States and are not listed on any national US securities exchange.

 

Enquiries:

 

Consort Medical plc

+44 (0) 1442 867 920

Jonathan Glenn - Chief Executive Officer

Paul Hayes - Chief Financial Officer

 

Disclosure Requirements of the Code

 

Under Rule 8.3(a) of the Code, any person who is interested in 1% or more of any class of relevant securities of an offeree company or of any securities exchange offeror (being any offeror other than an offeror in respect of which it has been announced that its offer is, or is likely to be, solely in cash) must make an Opening Position Disclosure following the commencement of the offer period and, if later, following the announcement in which any securities exchange offeror is first identified.

 

An Opening Position Disclosure must contain details of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror(s). An Opening Position Disclosure by a person to whom Rule 8.3(a) applies must be made by no later than 3.30 p.m. (London time) on the 10th business day following the commencement of the offer period and, if appropriate, by no later than 3.30 p.m. (London time) on the 10th business day following the announcement in which any securities exchange offeror is first identified. Relevant persons who deal in the relevant securities of the offeree company or of a securities exchange offeror prior to the deadline for making an Opening Position Disclosure must instead make a Dealing Disclosure.

 

Under Rule 8.3(b) of the Code, any person who is, or becomes, interested in 1% or more of any class of relevant securities of the offeree company or of any securities exchange offeror must make a Dealing Disclosure if the person deals in any relevant securities of the offeree company or of any securities exchange offeror. A Dealing Disclosure must contain details of the dealing concerned and of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror, save to the extent that these details have previously been disclosed under Rule 8. A Dealing Disclosure by a person to whom Rule 8.3(b) applies must be made by no later than 3.30 p.m. (London time) on the business day following the date of the relevant dealing.

 

If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire or control an interest in relevant securities of an offeree company or a securities exchange offeror, they will be deemed to be a single person for the purpose of Rule 8.3.

 

Opening Position Disclosures must also be made by the offeree company and by any offeror and Dealing Disclosures must also be made by the offeree company, by any offeror and by any persons acting in concert with any of them (see Rules 8.1, 8.2 and 8.4).

 

Details of the offeree and offeror companies in respect of whose relevant securities Opening Position Disclosures and Dealing Disclosures must be made can be found in the Disclosure Table on the Takeover Panel's website at www.thetakeoverpanel.org.uk, including details of the number of relevant securities in issue, when the offer period commenced and when any offeror was first identified. If you are in any doubt as to whether you are required to make an Opening Position Disclosure or a Dealing Disclosure, you should contact the Panel's Market Surveillance Unit on +44 (0) 207 638 0129.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RTTRTMFTMBJBBTP
Date   Source Headline
8th Apr 20159:57 amRNSDirector Declaration
1st Apr 20159:07 amRNSTotal Voting Rights
23rd Mar 20152:44 pmRNSHolding(s) in Company
12th Mar 20152:53 pmRNSHolding(s) in Company - Replacement
11th Mar 20159:10 amRNSHolding(s) in Company
23rd Feb 20157:00 amRNSVoke® licence - variation granted by MHRA
11th Feb 201511:12 amRNSDirectorate Change
4th Feb 20157:00 amRNSIntegrated Dose Counter Supply Agreement
3rd Feb 201511:37 amRNSHolding(s) in Company
2nd Feb 20159:43 amRNSTotal Voting Rights
29th Jan 20157:00 amRNS£2.2m investment in Atlas Genetics Series C
26th Jan 201512:47 pmRNSDirector/PDMR Shareholding
6th Jan 20153:48 pmRNSDirector/PDMR Shareholding
5th Jan 20152:46 pmRNSTotal Voting Rights
9th Dec 201410:37 amRNSDirector/PDMR Shareholding
4th Dec 20147:00 amRNSHalf Yearly Report
2nd Dec 20141:43 pmRNSBlocklisting Interim Review
28th Nov 201411:31 amBUSForm 8.3 - CSR PLC - Replacement
27th Nov 20142:53 pmBUSForm 8.3 - CSR PLC
27th Nov 20149:00 amRNSHolding(s) in Company
14th Nov 20142:23 pmRNSHolding(s) in Company
12th Nov 201411:09 amRNSAcquisition of Aesica Holdco Limited
12th Nov 201410:06 amRNSTotal Voting Rights
7th Nov 201410:23 amRNSHolding(s) in Company
6th Nov 201412:58 pmRNSHolding(s) in Company
5th Nov 201412:26 pmRNSAdditional Listing
5th Nov 201410:04 amRNSHolding(s) in Company
4th Nov 201412:45 pmRNSTotal Voting Rights
4th Nov 201412:36 pmRNSDirector/PDMR Shareholding
3rd Nov 20149:35 amRNSResults of Rump Placing
3rd Nov 20147:00 amRNSResults of Rights Issue
29th Oct 20144:51 pmRNSDirector/PDMR Shareholding
28th Oct 20145:02 pmRNSHolding(s) in Company
22nd Oct 20147:00 amRNSDevelopment Contract Award
21st Oct 20142:28 pmRNSGerman anti-trust clearance
17th Oct 20148:02 amRNSADMISSION OF NEW ORDINARY SHARES
16th Oct 201412:00 pmRNSResult of EGM
15th Oct 20141:30 pmRNSBlocklisting Interim Review
6th Oct 201410:19 amRNSDirector/PDMR Shareholding
2nd Oct 20141:55 pmRNSHolding(s) in Company
1st Oct 201411:47 amRNSTotal Voting Rights
30th Sep 20143:44 pmRNSPublication of Prospectus
30th Sep 20147:00 amRNSProposed acquisition of Aesica Holdco Limited
12th Sep 20147:00 amRNSMHRA Authorisation of the Voke Inhaler
5th Sep 20143:06 pmRNSHolding(s) in Company
4th Sep 20143:28 pmRNSResult of AGM
4th Sep 20147:00 amRNSInterim Management Statement
29th Jul 20144:28 pmRNSDirector/PDMR Shareholding
29th Jul 201412:10 pmRNSAnnual Financial Report
25th Jul 201410:45 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.